CN107427585A - 艾菲康唑的晶型 - Google Patents

艾菲康唑的晶型 Download PDF

Info

Publication number
CN107427585A
CN107427585A CN201580073938.9A CN201580073938A CN107427585A CN 107427585 A CN107427585 A CN 107427585A CN 201580073938 A CN201580073938 A CN 201580073938A CN 107427585 A CN107427585 A CN 107427585A
Authority
CN
China
Prior art keywords
efeconazole
crystalline
powder diffraction
ray powder
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073938.9A
Other languages
English (en)
Chinese (zh)
Inventor
伊太·埃丁
希拉·埃拉扎里-沙洛姆
奥里·罗里尔克
雅纳·塞里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wavelength Pharmaceuticals Ltd
Original Assignee
Perrigo API Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrigo API Ltd filed Critical Perrigo API Ltd
Publication of CN107427585A publication Critical patent/CN107427585A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580073938.9A 2015-01-20 2015-12-02 艾菲康唑的晶型 Pending CN107427585A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105390P 2015-01-20 2015-01-20
US62/105,390 2015-01-20
PCT/IL2015/051171 WO2016116919A1 (en) 2015-01-20 2015-12-02 Crystalline forms of efinaconazole

Publications (1)

Publication Number Publication Date
CN107427585A true CN107427585A (zh) 2017-12-01

Family

ID=56416514

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073938.9A Pending CN107427585A (zh) 2015-01-20 2015-12-02 艾菲康唑的晶型

Country Status (8)

Country Link
US (1) US20180002310A1 (enExample)
EP (1) EP3247399A4 (enExample)
JP (1) JP2018502165A (enExample)
CN (1) CN107427585A (enExample)
AU (1) AU2015379251A1 (enExample)
CA (1) CA2974180A1 (enExample)
IL (1) IL253479A0 (enExample)
WO (1) WO2016116919A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995434A (zh) * 2016-01-25 2017-08-01 广东东阳光药业有限公司 一种三唑类抗真菌药的晶型及其制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110770220B (zh) * 2017-05-19 2022-08-12 科研制药株式会社 艾菲康唑的制备及提纯方法
JP2022515696A (ja) * 2018-12-29 2022-02-22 威智医薬有限公司 エフィナコナゾールの調製方法
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1122598A (zh) * 1993-05-10 1996-05-15 科研制药株式会社 吡咯胺衍生物
WO2001007643A1 (en) * 1999-07-28 2001-02-01 Kaken Pharmaceutical Co., Ltd. Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating the drug effect of antimicrobial agent, and antimicrobial agents
CN103080100A (zh) * 2010-08-31 2013-05-01 科研制药株式会社 1-三唑-2-丁醇衍生物的制造方法
CN104292214A (zh) * 2014-09-24 2015-01-21 南京华威医药科技开发有限公司 艾氟康唑及其中间体的合成方法
CN104327047A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 艾菲康唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3437695B2 (ja) * 1993-05-10 2003-08-18 科研製薬株式会社 アゾリルアミン誘導体
WO2008081940A1 (ja) * 2006-12-28 2008-07-10 Kaken Pharmaceutical Co., Ltd. 真菌症治療用ゲル組成物
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
US20090175810A1 (en) * 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
FR2938066B1 (fr) * 2008-11-06 2010-12-17 Centre Nat Rech Scient Systeme et procede d'analyse quantitative de la composition elementaire de la matiere par spectroscopie du plasma induit par laser (libs)
AU2016261273A1 (en) * 2015-05-12 2017-12-07 Lupin Limited Process for the preparation of efinaconazole
US10125115B2 (en) * 2015-06-04 2018-11-13 Glenmark Pharmaceuticals Limited Process for the preparation of efinaconazole

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1122598A (zh) * 1993-05-10 1996-05-15 科研制药株式会社 吡咯胺衍生物
WO2001007643A1 (en) * 1999-07-28 2001-02-01 Kaken Pharmaceutical Co., Ltd. Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating the drug effect of antimicrobial agent, and antimicrobial agents
CN103080100A (zh) * 2010-08-31 2013-05-01 科研制药株式会社 1-三唑-2-丁醇衍生物的制造方法
CN104292214A (zh) * 2014-09-24 2015-01-21 南京华威医药科技开发有限公司 艾氟康唑及其中间体的合成方法
CN104327047A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 艾菲康唑的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRONOBU OGURA等: "Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents", 《CHEM. PHARM. BULL.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995434A (zh) * 2016-01-25 2017-08-01 广东东阳光药业有限公司 一种三唑类抗真菌药的晶型及其制备方法

Also Published As

Publication number Publication date
EP3247399A1 (en) 2017-11-29
AU2015379251A1 (en) 2017-07-27
WO2016116919A1 (en) 2016-07-28
CA2974180A1 (en) 2016-07-28
US20180002310A1 (en) 2018-01-04
EP3247399A4 (en) 2018-09-05
JP2018502165A (ja) 2018-01-25
IL253479A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
KR102642407B1 (ko) 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1H-1,2,4-트리아졸-3-일)페닐)아미노)-N-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
TWI589575B (zh) 苯并咪唑衍生物之新穎結晶型及其製備方法
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のｉ型結晶およびその製造法
US20080085903A1 (en) Novel crystalline forms of aripiprazole
RU2615509C2 (ru) Кристаллическая 7-{ (3s,4s)-3-[(циклопропиламино)метил]-4-фторпирролидин-1-ил} -6-фтор-1-(2-фторэтил)-8-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота
MX2013012190A (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
PT2077996E (pt) Processo de purificação de montelucaste e seus sais de amina
US20140256755A1 (en) Raltegravir Salts And Crystalline Forms Thereof
CN107427585A (zh) 艾菲康唑的晶型
WO2015138933A1 (en) Solid state forms of dolutegravir sodium
CN101730690A (zh) 磺酰胺化合物及其结晶
CN101774969B (zh) 硫酸伊伐布雷定及其i型结晶的制备方法
US20050277650A1 (en) Process for preparing aripirazole hydrate
TWI727517B (zh) 貝前列素-314d晶體及其製備方法
CN104487437B (zh) 恩曲他滨水杨酸盐及其晶型、制备方法和用途
WO2016058564A1 (en) Salts of bedaquiline
WO2024234619A1 (zh) 一种化合物的晶型、药物组合物及用途
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
JP2015007000A (ja) モンテルカスト遊離酸の結晶を製造する方法
US20200283381A1 (en) Solid state forms of elafibranor
CN103012295B (zh) 艾迪康唑的光学异构体及其制备方法与应用
US9000165B2 (en) Process for the preparation of anhydrous aripiprazole crystal form II
US20070149782A1 (en) Methods of preparing a crystalline form of 7-(4-chlorobutoxy)-3,4-dihydro-2(1h)-quinolinone and the use thereof in the synthesis of Aripiprazole
CN114634484A (zh) 改进的奥希替尼或其盐的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Bene Israel Barack

Applicant after: Wavelength Enterprise Limited

Address before: Bene Israel Barack

Applicant before: Perrigo API Co. Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171201

WD01 Invention patent application deemed withdrawn after publication